GoAI
Get started
MacroGenics, Inc. logo

MacroGenics, Inc.

MGNX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$4.10

+$0.03 · +0.74%

Aug 21, 4:00 PM ET

MGNX company overview

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

60

Fair Value

Momentum

66

Gaining

Sentiment

65

Bullish

Risk resilience

48

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Eric Risser
Listed since
Oct 10, 2013
Employees
293

Market position

Day range

Current $4.10

52-week range

Current $4.10

Open
$4.08
Previous close
$4.07
Volume
271.52K
0.27× average
Average volume
992.42K
Average daily volume
Market cap
260.61M USD
Beta
1.22
Market reference 1
50-day average
$4.2268
-3.00% below average
200-day average
$2.8886
+41.94% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-18.64×
P/B (TTM)
6.08×
P/S (TTM)
1.55×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
50.44%
Operating margin
-24.30%
Net margin
-8.70%

Financial health

Debt / equity
0.82×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends136%-21%-177%-333%Gross margin, FY2021: 96.50%Gross margin, FY2022: 95.08%Gross margin, FY2023: 85.62%Gross margin, FY2024: 91.71%Gross margin, FY2025: 71.12%Operating margin, FY2021: -268.09%Operating margin, FY2022: -80.94%Operating margin, FY2023: -294.17%Operating margin, FY2024: -74.54%Operating margin, FY2025: -48.72%Net margin, FY2021: -267.20%Net margin, FY2022: -79.83%Net margin, FY2023: -15.84%Net margin, FY2024: -45.14%Net margin, FY2025: -49.91%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 96.50%. Gross margin FY2022 95.08%. Gross margin FY2023 85.62%. Gross margin FY2024 91.71%. Gross margin FY2025 71.12%. Operating margin FY2021 -268.09%. Operating margin FY2022 -80.94%. Operating margin FY2023 -294.17%. Operating margin FY2024 -74.54%. Operating margin FY2025 -48.72%. Net margin FY2021 -267.20%. Net margin FY2022 -79.83%. Net margin FY2023 -15.84%. Net margin FY2024 -45.14%. Net margin FY2025 -49.91%.

Income trends

Revenue

149.5M USD+0.78%

Operating income

−72.84M USD+34.13%

Net income

−74.62M USD-11.43%
Income trends across reported periods185.3M USD44.17M USD−96.95M USD−238.08M USDRevenue, FY2021: 75.64M USDRevenue, FY2022: 150.02M USDRevenue, FY2023: 57.19M USDRevenue, FY2024: 148.34M USDRevenue, FY2025: 149.5M USDOperating income, FY2021: −202.8M USDOperating income, FY2022: −121.42M USDOperating income, FY2023: −168.24M USDOperating income, FY2024: −110.58M USDOperating income, FY2025: −72.84M USDNet income, FY2021: −202.12M USDNet income, FY2022: −119.76M USDNet income, FY2023: −9.06M USDNet income, FY2024: −66.97M USDNet income, FY2025: −74.62M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 75.64M USD. Revenue FY2022 150.02M USD. Revenue FY2023 57.19M USD. Revenue FY2024 148.34M USD. Revenue FY2025 149.5M USD. Operating income FY2021 −202.8M USD. Operating income FY2022 −121.42M USD. Operating income FY2023 −168.24M USD. Operating income FY2024 −110.58M USD. Operating income FY2025 −72.84M USD. Net income FY2021 −202.12M USD. Net income FY2022 −119.76M USD. Net income FY2023 −9.06M USD. Net income FY2024 −66.97M USD. Net income FY2025 −74.62M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue149.5M USD148.34M USD57.19M USD150.02M USD75.64M USD
Cost of goods sold43.18M USD12.3M USD8.22M USD7.38M USD2.65M USD
Gross profit106.32M USD136.04M USD48.97M USD142.63M USD72.99M USD
Research and development140M USD177.19M USD166.58M USD207.03M USD214.58M USD
Selling, general, and administrative39.16M USD71.05M USD52.19M USD58.95M USD63.01M USD
Operating expenses179.16M USD246.62M USD217.22M USD264.05M USD275.79M USD
Interest income3.4M USD9.42M USD9.69M USD1.7M USD680K USD
Interest expense8.51M USD1.12M USD1.43M USD——
Depreciation and amortization7.17M USD7.54M USD9.65M USD11.87M USD11.26M USD
Operating income−72.84M USD−110.58M USD−168.24M USD−121.42M USD−202.8M USD
Net income−74.62M USD−66.97M USD−9.06M USD−119.76M USD−202.12M USD

Company facts updated Aug 24, 2026.

MGNX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding MGNX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
7.11M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
6.25M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
2.46M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
2.09M
Weight
0.01%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.3M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
1.22M
Weight
0.02%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
886.36K
Weight
0.06%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
ALPS Medical Breakthroughs ETF logoALPS Medical Breakthroughs ETFSBIO
Market value
306.86K
Weight
0.13%
AUM
236.37M USD
Expense ratio
0.50%
Price / 1D
$69.11+0.80%

Continue in GoAI

Research MGNX

research.disclaimer